Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U 937 cells.
The human histiocytic cell line U 937, which expresses a number of monocyte markers and properties, was investigated with regard to its ability to be activated for NO and tumor necrosis factor (TNF) release after treatment with alkylphosphocholines (APC) and APC liposomes. Using APC multilamellar vesicles (MLV) a clear dose-dependent increase of NO production could be demonstrated for U 937 cells, whereas the corresponding soluble substances had no effect. The time course of NO release was characterised by a peak between 2 h and 12 h and a strong decrease after 24 h. LPS caused no NO release nor the production of TNF in U 937 cells. The simultaneous incubation of the cells with lipopolysaccharide and APC or APC-MLV, led to a strong increase in TNF production. Closer investigation of the time sequence of this synergistic effect demonstrated that cells, that had first been treated with hexadecylphosphocholine (HPC)-MLV and 4 h later with lipopolysaccharide secreted significantly more TNF into the supernatants than in the experiment where both substances were added simultaneously. From these results it was concluded that APC-MLV are possibly able to act as a primer in the process of lipopolysaccharide mediated TNF induction. Furthermore, a positive influence of phorbol 12-myristate 13-acetate (PMA) on the ability of U 937 cells to produce TNF following a treatment with HPC or HPC-MLV could be observed. PMA-pretreated cells were shown to release much more TNF compared to control cells, which led to the supposition that the immunomodifying activity of APC becomes effective only in more highly differentiated cell types.
Eue
I
I
Max Delbrück Centre for Molecular Medicine, Berlin, Germany.
Zeisig
R
R
Arndt
D
D
D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D006644:Histiocytes / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008081:Liposomes; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism; D009569:Nitric Oxide / Q000096:biosynthesis*; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D004337:Drug Carriers; D008081:Liposomes; D014409:Tumor Necrosis Factor-alpha; C094381:eicosanylphosphocholine; D010767:Phosphorylcholine; D009569:Nitric Oxide; C028810:dodecylphosphocholine; C039128:miltefosine; C031166:n-tetradecylphosphorylcholine